← Asymchem Laboratories Tian Jin overview

Asymchem Laboratories Tian Jin vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Asymchem Laboratories Tian Jin Co Ltd (002821.CS)

Q3 2026
▲3▼1

Asymchem rides CRO rally, but profit drop and FX hit temper gains

  • CRO sector rally lifts Asymchem A broad CRO sector surge, sparked by WuXi AppTec's strong half-year results and raised guidance, pushed Asymchem and peers to daily limit-up. This reflects renewed demand for drug R&D outsourcing, which supports Asymchem's order book and future revenue.

    Explains the main positive force behind the stock's recent price moves.

  • AsymBio secures major investment Asymchem Group and Hillhouse Qirui are investing 1.24 billion yuan in AsymBio, a biologics CDMO subsidiary. This capital injection supports capacity expansion and growth in high-growth areas like ADCs, strengthening Asymchem's long-term competitive position.

    Shows a concrete capital commitment that boosts growth prospects.

  • First-half profit falls despite revenue growth Asymchem's first-half net profit dropped 15.7% year on year to 520 million yuan, even as revenue rose 13.1%. The decline was mainly due to currency swings; excluding FX effects, adjusted profit rose 12.9%. The headline miss may pressure the stock short-term.

    Directly addresses the earnings miss that weighs on investor sentiment.

  • Backlog surges over 50%, signaling strong demand Asymchem's total orders on hand jumped 53.8% year on year to $1.67 billion, with new orders up 54.6%. This strong backlog, especially in emerging businesses like chemical and biological macromolecule CDMO, points to robust future revenue growth and supports the stock's valuation.

    Highlights a key forward-looking indicator that offsets profit concerns.

August 2026
▲3▼1

Asymchem rides CRO rally, but profit drop and FX hit temper gains

  • CRO sector rally lifts Asymchem A broad CRO sector surge, sparked by WuXi AppTec's strong half-year results and raised guidance, pushed Asymchem and peers to daily limit-up. This reflects renewed demand for drug R&D outsourcing, which supports Asymchem's order book and future revenue.

    Explains the main positive force behind the stock's recent price moves.

  • AsymBio secures major investment Asymchem Group and Hillhouse Qirui are investing 1.24 billion yuan in AsymBio, a biologics CDMO subsidiary. This capital injection supports capacity expansion and growth in high-growth areas like ADCs, strengthening Asymchem's long-term competitive position.

    Shows a concrete capital commitment that boosts growth prospects.

  • First-half profit falls despite revenue growth Asymchem's first-half net profit dropped 15.7% year on year to 520 million yuan, even as revenue rose 13.1%. The decline was mainly due to currency swings; excluding FX effects, adjusted profit rose 12.9%. The headline miss may pressure the stock short-term.

    Directly addresses the earnings miss that weighs on investor sentiment.

  • Backlog surges over 50%, signaling strong demand Asymchem's total orders on hand jumped 53.8% year on year to $1.67 billion, with new orders up 54.6%. This strong backlog, especially in emerging businesses like chemical and biological macromolecule CDMO, points to robust future revenue growth and supports the stock's valuation.

    Highlights a key forward-looking indicator that offsets profit concerns.

Latest
▲3▼1

Asymchem rides CRO rally, but profit drop and FX hit temper gains

  • CRO sector rally lifts Asymchem A broad CRO sector surge, sparked by WuXi AppTec's strong half-year results and raised guidance, pushed Asymchem and peers to daily limit-up. This reflects renewed demand for drug R&D outsourcing, which supports Asymchem's order book and future revenue.

    Explains the main positive force behind the stock's recent price moves.

  • AsymBio secures major investment Asymchem Group and Hillhouse Qirui are investing 1.24 billion yuan in AsymBio, a biologics CDMO subsidiary. This capital injection supports capacity expansion and growth in high-growth areas like ADCs, strengthening Asymchem's long-term competitive position.

    Shows a concrete capital commitment that boosts growth prospects.

  • First-half profit falls despite revenue growth Asymchem's first-half net profit dropped 15.7% year on year to 520 million yuan, even as revenue rose 13.1%. The decline was mainly due to currency swings; excluding FX effects, adjusted profit rose 12.9%. The headline miss may pressure the stock short-term.

    Directly addresses the earnings miss that weighs on investor sentiment.

  • Backlog surges over 50%, signaling strong demand Asymchem's total orders on hand jumped 53.8% year on year to $1.67 billion, with new orders up 54.6%. This strong backlog, especially in emerging businesses like chemical and biological macromolecule CDMO, points to robust future revenue growth and supports the stock's valuation.

    Highlights a key forward-looking indicator that offsets profit concerns.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.